Has Trinity Bivalacqua, MD received payments from drug or device companies?

Yes. Drug and device makers reported $100,120 in general payments to Trinity Bivalacqua, MD across 73 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Trinity Bivalacqua, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Trinity Bivalacqua, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Trinity Bivalacqua, MD

Urology · Philadelphia, PANPI 1265579254

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $81,042 of the $100,120 with a category attached, or 80.9%. 15 manufacturers reported payments, led by Urogen Pharma, Inc. at 26.6% of the total. Reporting peaked in 2019 at $28,698 and has fallen 69.7% since, to $8,695 in 2025. Among urology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$100,120in general payments, 2019–2025

Across 73 payments — averaging $1371.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Urogen Pharma, Inc.$27K
Ferring Pharmaceuticals Inc.$19K
Photocure Inc$17K
Ferring Pharmaceuticals AS$16K
Pfizer$6K
Verity Pharmaceuticals Inc.$5K
plus $11K from 9 others

$261,334in research payments, 2019–2025

Across 12 payments — averaging $21,778 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$156K
KARL Storz Endoscopy-america$78K
Janssen Research & Development, LLC$28K

What the payments were for

Consulting fees$81,04281%
Speaking & faculty fees$13,05513%
Travel & lodging$3,0603%
Food & beverage$2,9633%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Urogen Pharma, Inc.	17	$26,628
Ferring Pharmaceuticals Inc.	16	$18,845
Photocure Inc	10	$17,427
Ferring Pharmaceuticals AS	3	$15,650
Pfizer	11	$6,402
Verity Pharmaceuticals Inc.	2	$4,600
Janssen Global Services, LLC	2	$3,746
Regeneron	1	$3,450
E.r. Squibb & Sons, L.L.C.	1	$1,192
Merck	1	$1,000
Johnson & Johnson(2 entities)	2	$622
Coloplast	3	$300
Seagen Inc.	1	$163
Baxter Healthcare	2	$59
Astellas Pharma US Inc	1	$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Cysview$17,296
ADSTILADRIN$10,850
JELMYTO$10,537
PADCEV$6,289
LIBTAYO$3,450
TRELSTAR$3,000
TITAN$144
SenSura Mio$122
RYBREVANT$117
CARVYKTI$117

How this compares

$100,120 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$183,798

Medicare patients

358

Services billed

860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Methenamine Hippurate	15	$1,266
Tamsulosin Hcl	70	$771
Dutasteride	11	$743
Oxybutynin Chloride	36	$394
Levofloxacin	14	$115
Finasteride	15	$22

Paid to pharmacies, not to this prescriber.

Other urology in Philadelphia

Demetrius BagleyPhiladelphia$739K
Daniel EunPhiladelphia$226K
Leonard GomellaPhiladelphia$190K
Phillip GinsbergPhiladelphia$145K
Edouard TrabulsiPhiladelphia$137K
Siobhan HartiganPhiladelphia$121K
Paul ChungPhiladelphia$120K
William JaffePhiladelphia$119K
Robert UzzoPhiladelphia$111K
Jay SimhanPhiladelphia$110K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →